OLOPATADINE HYDROCHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Olopatadine hydrochloride is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits histamine release from mast cells and prevents histamine-induced effects such as increased vascular permeability and pruritus.
| Metabolism | Olopatadine is predominantly metabolized in the liver via glucuronidation and to a lesser extent via cytochrome P450 (CYP450) isoenzymes, primarily CYP3A4. |
| Excretion | Primarily renal excretion (60-70% unchanged), with minor biliary/fecal elimination (~30% as metabolites) |
| Half-life | Terminal elimination half-life of 8–12 hours in healthy adults; prolonged in hepatic impairment (up to 18 hours) |
| Protein binding | ~55% bound primarily to albumin |
| Volume of Distribution | 0.5–1.0 L/kg; moderate distribution in total body water |
| Bioavailability | Ophthalmic: minimal systemic absorption (<2%); intranasal: ~30% systemic bioavailability |
| Onset of Action | Ophthalmic: 30–60 minutes; intranasal: ~15 minutes |
| Duration of Action | Ophthalmic: 8–12 hours; intranasal: 12–24 hours; clinical effect persists for 8–12 hours after single dose |
| Molecular Weight | 373.9 |
| Action Class | Antihistamine / Mast Cell Stabilizer |
One drop of 0.1% or 0.2% ophthalmic solution in each affected eye twice daily (every 6-8 hours) for 0.1%; once daily for 0.2%.
| Dosage form | SOLUTION |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment. Use with caution in severe renal impairment (CrCl < 30 mL/min) due to limited data; no specific dose adjustment recommended. |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Use with caution in severe hepatic impairment (Child-Pugh C) due to lack of data. |
| Pediatric use | Children ≥2 years: Same as adult dosing (one drop of 0.1% ophthalmic solution twice daily or 0.2% once daily). For children <2 years, safety and efficacy not established. |
| Geriatric use | No specific dosage adjustment required. Use same dosing as adults. Monitor for ocular adverse effects due to possible age-related reduced tear production and ocular surface changes. |
| 1st trimester | Insufficient data in pregnant women; animal studies not sufficient to assess risk. Use only if potential benefit justifies risk. |
| 2nd trimester | Insufficient data; consider risk-benefit. No known teratogenicity. |
| 3rd trimester | Insufficient data; risk-benefit assessment needed. No known adverse effects on fetus or neonate. |
Clinical note
No significant drug interactions For ophthalmic use only may cause mild transient burning or stinging.
| Placental transfer | Likely crosses placenta due to low molecular weight (373.9 Da) but data lacking. |
| Breastfeeding | Not known if excreted in human milk; due to low molecular weight, likely present. Caution advised; monitor infant for drowsiness. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Common Effects | Eye pain Eye irritation Abnormal eye sensation Eye discomfort Sleepiness Weakness Dryness in mouth |
| Serious Effects | Hypersensitivity reactions (angioedema, urticaria, dyspnea), Corneal ulceration or keratitis (with prolonged use), Increased intraocular pressure (in predisposed patients), Severe conjunctival hyperemia or edema |
Hypersensitivity to olopatadine hydrochloride or any excipients
| Precautions | Not for injection or oral use., Avoid contamination of the container tip., May cause transient burning or stinging upon instillation., Use with caution in patients with known hypersensitivity to any component of the formulation., Pregnancy and lactation: use only if clearly needed. |
| Food/Dietary | No known food interactions. Grapefruit juice does not affect olopatadine metabolism. No dietary restrictions required. |
Loading safety data…
| L3 |
| Teratogenic Risk | Olopatadine hydrochloride is classified as FDA Pregnancy Category C. Animal studies have shown no teratogenic effects at doses up to 600 mg/kg/day (rat) and 400 mg/kg/day (rabbit). There are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out; use only if potential benefit justifies potential risk to the fetus. |
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. Monitor for maternal adverse effects such as somnolence or headache. |
| Fertility Effects | No significant effects on fertility observed in animal studies. In rats, there was no impairment of fertility at oral doses up to 200 mg/kg/day. |
| Clinical Pearls | Olopatadine is a dual-acting ophthalmic antihistamine (H1 receptor antagonist) and mast cell stabilizer. For allergic conjunctivitis, onset of action is within minutes; maximum efficacy may require up to 2 weeks of regular use. Use caution in patients with dry eye or contact lens wear; lenses should be removed before instillation and may be reinserted after 10 minutes. Avoid concurrent use with other topical ophthalmic products containing benzalkonium chloride (common preservative) due to possible precipitation. |
| Patient Advice | Do not touch the dropper tip to any surface (including eyes) to avoid contamination. · Remove contact lenses before using and wait at least 10 minutes after instillation before reinserting. · If used with other eye drops, wait at least 5 minutes between each medication. · Temporary blurred vision may occur; do not drive or operate machinery until vision clears. · Store at room temperature, away from moisture and heat. · Do not use if solution changes color or becomes cloudy. |